Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

Inclusion Criteria:

* Male ≥ 18 years of age;
* For patients with newly diagnosed prostate cancer : (1) adult patients with PCa confirmed by biopsy; (2) no any form of therapy against PCa within last three months; (3) planned surgical treatment;
* For patients with suspected recurrence of prostate cancer: (1)Histopathologically confirmed prostate adenocarcinoma per original diagnosis, with subsequent definitive therapy; (2)Suspected recurrence of prostate cancer based on rising PSA after definitive therapy on the basis of: Post-radical prostatectomy: Detectable or rising PSA level ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL ; or Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir;
* Life expectancy ≥3 months as determined by the investigator;
* Able and willing to provide informed consent and comply with protocol requirements.

Exclusion Criteria:

* Known allergic history to fluoride 18F-Thretide injection and/or 99mTc-MDP or its excipients;
* Patients who cannot tolerate intravenous administration (such as a history of needle sickness or blood sickness);
* Those who are not suitable for or unable to complete PET or other imaging examinations due to special reasons, including claustrophobia and radiophobia, etc.
* Practitioners requiring prolonged exposure to radioactive conditions;
* Serious diseases of the heart, kidney, lung, vascular, nervous and psychiatric systems, immune deficiency diseases and hepatitis/cirrhosis;
* Have been diagnosed with clinical recurrence of prostate cancer;
* Patients receiving ADT treatment or chemotherapy;
* Patients who participated in clinical trials of radiopharmaceuticals within the previous 1 year;
* Participated in other interventional clinical trials within 1 month prior to screening;
* There are other conditions that the researcher considers inappropriate to participate in this study.